Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases, will host a conference call and webcast to discuss its Q2 2025 financial results on Thursday, August 14, 2025, at 8:30 AM ET.
The company will provide updates on its financial performance for the quarter ended June 30, 2025, along with recent business developments. Investors can access the call through U.S. (1-877-407-0789) or International (1-201-689-8562) dial-in numbers using Conference ID 13754425. A replay will be available on the company's website.
Traws Pharma (NASDAQ: TRAW), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per le malattie virali respiratorie, terrà una conference call e una webcast per discutere i suoi risultati finanziari del secondo trimestre 2025 il giovedì 14 agosto 2025 alle 8:30 AM ET.
L'azienda fornirà aggiornamenti sulle performance finanziarie relative al trimestre conclusosi il 30 giugno 2025, insieme alle ultime novità aziendali. Gli investitori potranno partecipare alla chiamata chiamando i numeri statunitensi (1-877-407-0789) o internazionali (1-201-689-8562) utilizzando l'ID conferenza 13754425. Una registrazione sarà disponibile sul sito web dell'azienda.
Traws Pharma (NASDAQ: TRAW), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar terapias para enfermedades virales respiratorias, realizará una llamada conferencia y una transmisión en vivo para discutir sus resultados financieros del segundo trimestre de 2025 el jueves 14 de agosto de 2025 a las 8:30 AM ET.
La compañía proporcionará actualizaciones sobre su desempeño financiero para el trimestre finalizado el 30 de junio de 2025, junto con los desarrollos recientes del negocio. Los inversionistas podrán acceder a la llamada a través de los números de marcación en EE. UU. (1-877-407-0789) o internacionales (1-201-689-8562) utilizando el ID de conferencia 13754425. Una repetición estará disponible en el sitio web de la empresa.
Traws Pharma (NASDAQ: TRAW)는 호흡기 바이러스 질환 치료제 개발에 주력하는 임상 단계의 바이오제약 회사로서, 2025년 2분기 재무 실적을 논의하기 위해 2025년 8월 14일 목요일 오전 8시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다.
회사는 2025년 6월 30일로 종료된 분기의 재무 실적과 최근 사업 현황에 대해 업데이트할 예정입니다. 투자자들은 미국(1-877-407-0789) 또는 국제(1-201-689-8562) 전화번호를 통해 컨퍼런스 ID 13754425를 사용하여 콜에 참여할 수 있습니다. 녹음본은 회사 웹사이트에서 제공될 예정입니다.
Traws Pharma (NASDAQ : TRAW), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour les maladies virales respiratoires, organisera une conférence téléphonique et une webdiffusion pour discuter de ses résultats financiers du deuxième trimestre 2025 le jeudi 14 août 2025 à 8h30 ET.
La société fournira des mises à jour sur ses performances financières pour le trimestre clos le 30 juin 2025, ainsi que sur les récents développements commerciaux. Les investisseurs pourront accéder à l'appel via les numéros d'appel américains (1-877-407-0789) ou internationaux (1-201-689-8562) en utilisant l'ID de conférence 13754425. Une rediffusion sera disponible sur le site web de la société.
Traws Pharma (NASDAQ: TRAW), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien für virale Atemwegserkrankungen spezialisiert hat, wird eine Telefonkonferenz und ein Webcast veranstalten, um seine Finanzergebnisse für das zweite Quartal 2025 am Donnerstag, den 14. August 2025, um 8:30 Uhr ET zu besprechen.
Das Unternehmen wird Updates zu seiner finanziellen Leistung für das zum 30. Juni 2025 abgeschlossene Quartal sowie zu den aktuellen Geschäftsentwicklungen geben. Investoren können über die US-Telefonnummer (1-877-407-0789) oder die internationale Nummer (1-201-689-8562) mit der Konferenz-ID 13754425 an dem Anruf teilnehmen. Eine Aufzeichnung wird auf der Website des Unternehmens verfügbar sein.
- None.
- None.
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.
Conference Call and Webcast Information
- Date: Thursday, August 14, 2025, at 8:30 AM ET
- Participant Dial-in (U.S.): 1-877-407-0789
- Participant Dial-in (International): 1-201-689-8562
- Conference ID: 13754425
- Webcast Access: Click Here
A replay of the webcast will be available on the Investors section of the Traws website at https://www.trawspharma.com/corporate-events-presentations.
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).
Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at https://www.ir.trawspharma.com/partnering.
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
FAQ
When will Traws Pharma (NASDAQ: TRAW) report Q2 2025 earnings?
How can investors access Traws Pharma's Q2 2025 earnings call?
Where can I find the replay of Traws Pharma's Q2 2025 earnings call?
What does Traws Pharma (TRAW) specialize in?
